NeoGenomics Inc (NEO)
14.93
+0.79
(+5.59%)
USD |
NASDAQ |
Nov 05, 16:00
14.93
0.00 (0.00%)
After-Hours: 16:06
NeoGenomics Revenue (Quarterly): 164.50M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 164.50M |
| March 31, 2024 | 156.24M |
| December 31, 2023 | 155.55M |
| September 30, 2023 | 151.95M |
| June 30, 2023 | 146.92M |
| March 31, 2023 | 137.22M |
| December 31, 2022 | 138.70M |
| September 30, 2022 | 128.78M |
| June 30, 2022 | 125.07M |
| March 31, 2022 | 117.17M |
| December 31, 2021 | 125.73M |
| September 30, 2021 | 121.34M |
| June 30, 2021 | 121.72M |
| March 31, 2021 | 115.53M |
| December 31, 2020 | 126.00M |
| September 30, 2020 | 125.44M |
| June 30, 2020 | 86.98M |
| March 31, 2020 | 106.03M |
| December 31, 2019 | 106.87M |
| September 30, 2019 | 104.67M |
| June 30, 2019 | 101.71M |
| March 31, 2019 | 95.58M |
| December 31, 2018 | 76.48M |
| September 30, 2018 | 69.10M |
| June 30, 2018 | 67.75M |
| Date | Value |
|---|---|
| March 31, 2018 | 63.42M |
| December 31, 2017 | 61.42M |
| September 30, 2017 | 59.14M |
| June 30, 2017 | 62.26M |
| March 31, 2017 | 57.43M |
| December 31, 2016 | 48.22M |
| September 30, 2016 | 60.76M |
| June 30, 2016 | 63.13M |
| March 31, 2016 | 59.70M |
| December 31, 2015 | 27.28M |
| September 30, 2015 | 25.13M |
| June 30, 2015 | 24.37M |
| March 31, 2015 | 23.03M |
| December 31, 2014 | 25.00M |
| September 30, 2014 | 23.22M |
| June 30, 2014 | 20.67M |
| March 31, 2014 | 18.18M |
| December 31, 2013 | 18.32M |
| September 30, 2013 | 16.88M |
| June 30, 2013 | 15.60M |
| March 31, 2013 | 15.66M |
| December 31, 2012 | 14.89M |
| September 30, 2012 | 14.20M |
| June 30, 2012 | 15.61M |
| March 31, 2012 | 15.16M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
86.98M
Minimum
Jun 2020
164.50M
Maximum
Jun 2024
129.36M
Average
125.73M
Median
Dec 2021
Revenue (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 182.55M |
| Hologic Inc | 1.011B |
| Ekso Bionics Holdings Inc | 4.129M |
| T2 Biosystems Inc | 1.952M |
| CEL-SCI Corp | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -18.64M |
| Total Expenses (Quarterly) | 184.90M |
| EPS Diluted (Quarterly) | -0.15 |
| Enterprise Value | 1.964B |
| Gross Profit Margin (Quarterly) | 44.07% |
| Profit Margin (Quarterly) | -11.33% |
| Earnings Yield | -4.15% |
| Normalized Earnings Yield | -3.790 |